Acceleron Pharma Inc  

(Public, NASDAQ:XLRN)   Watch this stock  
Find more results for GEORGE A. NADER´┐Ż
33.93
-0.52 (-1.51%)
After Hours: 33.93 0.00 (0.00%)
Jul 28, 4:56PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 33.60 - 35.09
52 week 20.00 - 50.86
Open 34.53
Vol / Avg. 170,845.00/314,160.00
Mkt cap 1.33B
P/E     -
Div/yield     -
EPS -1.33
Shares 37.22M
Beta     -
Inst. own 90%
Aug 4, 2016
Q2 2016 Acceleron Pharma Inc Earnings Release (Tentative) - 9:30AM EDT - Add to calendar
Jun 21, 2016
Acceleron Pharma Inc at JMP Securities Life Sciences Conference
Jun 10, 2016
Acceleron Pharma Inc to Review Updated Luspatercept Results Presented at the 21st Congress of the European Hematology Association - Webcast
Jun 8, 2016
Acceleron Pharma Inc at Jefferies Healthcare Conference
Jun 3, 2016
Acceleron Pharma Inc Annual Shareholders Meeting (Estimated)
Jun 2, 2016
Acceleron Pharma Inc Annual Shareholders Meeting
May 23, 2016
Acceleron Pharma Inc at UBS Global Healthcare Conference
May 5, 2016
Acceleron Pharma Inc at Deutsche Bank Health Care Conference
May 5, 2016
Q1 2016 Acceleron Pharma Inc Earnings Release
May 5, 2016
Q1 2016 Acceleron Pharma Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 27.81% -353.06%
Operating margin -21.74% -336.40%
EBITD margin - -329.91%
Return on average assets 9.31% -38.42%
Return on average equity 10.99% -48.12%
Employees 102 -
CDP Score - -

Address

128 Sidney St
CAMBRIDGE, MA 02139-4239
United States - Map
+1-617-6499200 (Phone)
+1-617-6499988 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Acceleron Pharma Inc. is a United States-based clinical stage biopharmaceutical company. The Company focuses on discovering and developing therapies to treat a range of diseases. Its therapeutic candidate, luspatercept, is being evaluated in Phase III studies for the treatment of the hematologic diseases myelodysplastic syndromes (MDS) and beta-thalassemia. Its Sotatercept is an investigational protein therapeutic that manages red blood cell levels by targeting molecules in the transforming growth factor beta (TGF-β) superfamily, which is being evaluated in Phase IIa studies. Its Dalantercept is an investigational protein therapeutic that inhibits angiogenesis by preventing bone morphogenetic proteins 9 (BMP) and BMP10, proteins in the TGF-β superfamily, which is being evaluated in Phase II studies. Its ACE-083 is an investigational protein therapeutic that helps to manage muscle mass and strength in specific muscles and muscle groups, which is being evaluated in Phase I studies.

Officers and directors

Francois E. Nader M.D. Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
John L Knopf President, Chief Executive Officer, Director
Age: 63
Bio & Compensation  - Reuters
Kevin F. McLaughlin Chief Financial Officer, Senior Vice President, Treasurer
Age: 58
Bio & Compensation  - Reuters
Steven D. Ertel Chief Operating Officer, Executive Vice President
Age: 45
Bio & Compensation  - Reuters
Matthew L. Sherman M.D. Executive Vice President and Chief Medical Officer
Age: 56
Bio & Compensation  - Reuters
Ravindra Kumar Ph.D Chief Scientific Officer, Vice President
Age: 55
Bio & Compensation  - Reuters
John D. Quisel J.D., Ph.D. Vice President, General Counsel, Secretary
Age: 43
Bio & Compensation  - Reuters
Terrence C. Kearney Director
Age: 61
Bio & Compensation  - Reuters
Thomas A. McCourt Director
Age: 58
Bio & Compensation  - Reuters
Jean M. George Independent Director
Age: 57
Bio & Compensation  - Reuters